Daiichi Sankyo to Colaborate with Merck KGaA and Pfizer in Development...

This week Daiichi Sankyo confirmed a clinical research collaboration with Merck KGaA, Darmstadt, Germany and Pfizer to evaluate trastuzumab deruxtecan*, an antibody-drug conjugate or...

Executives from American Express and J.P. Morgan Join St. Baldrick’s Foundation...

The St. Baldrick's Foundation, the largest private funder of some of the most brilliant (clinical) research in childhood cancer, has added two new members...

Phase Ib/II Data of Durvalumab Plus Danvatirsen Shows Promise in Head...

New clinical and safety results from a phase Ib/II trial in recurrent metastatic head and neck cancer, presented at the annual meeting of the...

Novartis Plans to Acquire Endocyte to Expand Expertise in Radiopharmaceuticals

Earlier this month Swiss-based Novartis announced that it has entered into an agreement and plan of merger with Endocyte, a US-based biopharmaceutical company focused...

NanoValent Receives NIH SBIR Funding for Antibody-conjugated Nanoparticle Technology

The National Institute of Health's (NIH) Small Business Innovation Research (SBIR) Program has confirmed that it has awarded first year funding for two separate...

Study Shows Trade and Patent Changes Could Increase Healthcare Cost by...

In the second part of its 2018 annual report, CPhI Worldwide, the world’s largest pharma event taking place later this year in Madrid, Spain, Dilip...

Hemispherx Biopharma Releases Rintatolimod in EAP-program to Dutch Pancreatic Cancer Patients

Rintatolimod (Ampligen®; Hemispherx Biopharma) is a mismatched, double-stranded RNA molecule with immunomodulatory and antiviral properties. The drug acts as a Toll-like Receptor 3 (TLR3)...

Phase III Trial of Anti-PD-1 Antibody Tislelizumab + Chemotherapy Initiated as...

BeiGene, a commercial-stage biopharmaceutical company focused on developing and commercializing innovative molecularly-targeted and immuno-oncology drugs, has dosed the first patient dosed in a Phase...

Clinigen Group Acquires Global Rights to Novartis’ Proleukin®

The United Kingdom-based Clinigen Group has bought the global rights to Proleukin®, also known as Aldesleukin (recombinant interleukin-2; rIL2) outside the USA from Swiss...

Griffith R. Harsh IV to Lead Neurological Surgery at UC Davis

Renowned surgeon, scientist and educator Griffith Rutherford Harsh IV has been selected as chair of the Department of Neurological Surgery and the Julian R....

Latest